Browsing: Teclistamab

Teclistamab-cqyv (Tecvayli) plus talquetamab-tgvs (Talvey), a dual BCMA- and GPRC5D-targeting regimen, and talquetamab plus pomalidomide (Pomalyst) each significantly improved progression-free…

Induction therapy consisting of teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid), with or without bortezomib (Velcade), was feasible and…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of an indication…

BCMA-directed CAR T-cell therapy demonstrated superior overall survival (OS) outcomes, albeit with a higher incidence of immune-mediated toxicities, compared with…

Linvoseltamab (Lynozyfic) showed statistically significant improvements in outcomes like progression-free survival (PFS) and duration of response (DOR) compared with teclistamab-cqyv…

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Roberto Mina, MD, of the Winship Cancer Institute of…

This study included MM patients before their first anti-BCMA CAR therapy who had received their most recent dose of Teclistamab…

In March, the FDA approved teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro), introducing a new therapeutic option for patients…

Teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) has produced some of the “most exciting data” observed in relapsed/refractory multiple…

The FDA granted approval to teclistamab-cqyv (Tecvayli) in combination with daratumumab hyaluronidase-fihj as a treatment for adults with relapsed/refractory multiple…